Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$0.54
+11.3%
$0.74
$0.40
$7.29
$47.79M0.664.30 million shs5.42 million shs
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.54
+4.1%
$2.85
$0.89
$13.48
$12.57M0.7916,515 shs188,823 shs
Elutia Inc. stock logo
ELUT
Elutia
$1.16
+3.6%
$1.10
$0.50
$2.64
$47.92M0.75150,773 shs75,010 shs
HSTC
HST Global
$0.70
$0.64
$0.00
$1.05
$49.13M-366.53185 shs817 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+1.92%-7.78%-38.58%-49.22%-88.40%
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+4.96%+2.07%-51.32%-65.26%-40.80%
Elutia Inc. stock logo
ELUT
Elutia
-0.88%-6.67%+12.00%-2.61%-34.88%
HSTC
HST Global
0.00%-15.66%-29.29%+40.00%-15.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$0.54
+11.3%
$0.74
$0.40
$7.29
$47.79M0.664.30 million shs5.42 million shs
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.54
+4.1%
$2.85
$0.89
$13.48
$12.57M0.7916,515 shs188,823 shs
Elutia Inc. stock logo
ELUT
Elutia
$1.16
+3.6%
$1.10
$0.50
$2.64
$47.92M0.75150,773 shs75,010 shs
HSTC
HST Global
$0.70
$0.64
$0.00
$1.05
$49.13M-366.53185 shs817 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+1.92%-7.78%-38.58%-49.22%-88.40%
Cel-Sci Corporation stock logo
CVM
Cel-Sci
+4.96%+2.07%-51.32%-65.26%-40.80%
Elutia Inc. stock logo
ELUT
Elutia
-0.88%-6.67%+12.00%-2.61%-34.88%
HSTC
HST Global
0.00%-15.66%-29.29%+40.00%-15.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.25
Hold$25.674,631.18% Upside
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00
N/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
2.50
Moderate Buy$6.00417.24% Upside
HSTC
HST Global
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CVM, ELUT, HSTC, and ATYR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Reiterated RatingSell (D-)
5/20/2026
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
UpgradeHoldStrong-Buy
4/10/2026
Elutia Inc. stock logo
ELUT
Elutia
UpgradeSell (D+)Hold (C-)
3/6/2026
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Reiterated RatingBuy
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$190K279.96N/AN/A$0.59 per share0.92
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/A$0.81 per shareN/A
Elutia Inc. stock logo
ELUT
Elutia
$12.29M4.04N/AN/A$0.53 per share2.19
HSTC
HST Global
$520K94.49N/AN/A$0.12 per share5.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$74.12M-$0.73N/AN/AN/AN/A-100.14%-73.55%8/6/2026 (Estimated)
Cel-Sci Corporation stock logo
CVM
Cel-Sci
-$25.41M-$9.77N/AN/AN/AN/A-274.86%-126.47%N/A
Elutia Inc. stock logo
ELUT
Elutia
$53.38M$0.86N/AN/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)
HSTC
HST Global
-$860KN/AN/AN/AN/AN/AN/AN/AN/A

Latest CVM, ELUT, HSTC, and ATYR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q1 2026
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.16-$0.11+$0.05-$0.11N/AN/A
5/15/2026Q2 2026
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/A-$0.67N/A-$0.67N/AN/A
5/14/2026Q1 2026
Elutia Inc. stock logo
ELUT
Elutia
-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million
3/11/2026Q4 2025
Elutia Inc. stock logo
ELUT
Elutia
-$0.14-$0.14N/A$1.48$3.30 million$3.30 million
3/5/2026Q4 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.14+$0.04-$0.14$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/AN/A
Elutia Inc. stock logo
ELUT
Elutia
N/AN/AN/AN/AN/A
HSTC
HST Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/A
5.78
5.78
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.64
0.60
0.54
Elutia Inc. stock logo
ELUT
Elutia
N/A
2.05
1.94
HSTC
HST Global
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Cel-Sci Corporation stock logo
CVM
Cel-Sci
12.08%
Elutia Inc. stock logo
ELUT
Elutia
74.03%
HSTC
HST Global
N/A

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5.75%
Cel-Sci Corporation stock logo
CVM
Cel-Sci
9.93%
Elutia Inc. stock logo
ELUT
Elutia
27.60%
HSTC
HST Global
65.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5398.05 million92.41 millionOptionable
Cel-Sci Corporation stock logo
CVM
Cel-Sci
438.49 million7.65 millionOptionable
Elutia Inc. stock logo
ELUT
Elutia
18042.78 million30.98 millionNot Optionable
HSTC
HST Global
170.19 million23.99 millionNot Optionable

Recent News About These Companies

HST Global Inc.
HSTC HST Global, Inc.
HST Global Delays Yearly Report Filing
HST Global Delays Form 10-K Filing
HST Global Inc HSTC
CKNW homepage
Vinaconex Investment and Tourism Development JSC
Lof International Dairy Products JSC
Hung Hau Agricultural Corp.
Viettel Global Investment JSC VGI
Global Electrical Technology Corp.
Global Surgery Track
Viettel Global Investment JSC
VNG Corp VNZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$0.54 +0.06 (+11.30%)
Closing price 04:00 PM Eastern
Extended Trading
$0.53 -0.01 (-2.30%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Cel-Sci stock logo

Cel-Sci NYSEAMERICAN:CVM

$1.54 +0.06 (+4.05%)
Closing price 04:10 PM Eastern
Extended Trading
$1.55 +0.01 (+0.45%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Elutia stock logo

Elutia NASDAQ:ELUT

$1.16 +0.04 (+3.57%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

HST Global OTCMKTS:HSTC

$0.70 0.00 (0.00%)
As of 05/27/2026 09:30 AM Eastern

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.